1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

AgeneBio, Inc.

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Location

Baltimore MD US

Primary Industry

Biotechnology

About

Based in Maryland, US, AgeneBio Inc. provides a clinical program that aims to treat Alzheimer’s dementia. The company was founded by Michela Gallagher, who is leading the firm as CEO, as of 2024. In November 2013, the firm raised USD 1 million in a Series A funding round by a firm. The company engages in developing therapies that focus on the underlying causes of neurodegenerative illnesses. The product portfolio of AgeneBio comprises a GABA(A) α5 Discovery Programme for a variety of untreated illnesses such as schizophrenia, autism, and aMCI, and AGB101, a therapeutic candidate intended to address moderate cognitive impairment (MCI) resulting from Alzheimer's disease.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.agenebio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo